Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Under-the-skin efgartigimod wins approval in UK for gMG adults

An under-the-skin, or subcutaneous, injectable formulation of efgartigimod alfa has been approved in the U.K. as an add-on therapy for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR). This new formulation will be marketed in the U.K. as Subcutaneous Vyvgart. In…

MicroRNAs in blood may help diagnose ocular MG, study suggests

Three microRNAs (miRNAs) — small strands of RNA that regulate protein production — in blood samples accurately identified people with early-onset ocular myasthenia gravis (OMG) and distinguished them from early-onset generalized myasthenia gravis (gMG) patients and healthy people in a recent study. “These results suggested that the three…

Caregiver burden with MG rises with symptom severity, depression

Among caregivers of people with myasthenia gravis (MG) living in Northwest China, care burden rises with disease severity and the degree of the patient’s depression, a study reported. According to its researchers, this is primarily driven by patients’ inability to participate more fully in household chores, and the increasing…

KYV-101 found safe, effective for woman with severe gMG

Kyverna Therapeutics’ investigational cell therapy KYV-101 safely and effectively improved muscle strength and reduced fatigue in a woman with severe, hard-to-treat generalized myasthenia gravis (gMG), according to a case report. The patient was treated based on an individual case evaluation and outside of a clinical trial. “This groundbreaking…

Recipharm, Ahead team up to develop new treatment for MG

Recipharm is partnering with Ahead Therapeutics to develop a new type of therapy to reestablish immune tolerance and prevent the self-reactive immune attacks that cause myasthenia gravis (MG). “Together with our partner, we are determined to help them turn hope into reality for people living with myasthenia…

Thymectomy is effective in children, adolescents with MG: Study

A thymectomy, or surgical removal of the thymus gland, was effective for children and adolescents with myasthenia gravis (MG), as indicated by lower medication use and healthcare utilization after surgery, a study reports. Demographic characteristics like age, sex, ethnicity, insurance payer type, residential region, and the surgical approach…

Ocular MG symptoms can be eased with immunosuppressants: Study

Immunosuppressive therapies, administered with or without acetylcholinesterase inhibitors, helped ease symptoms of ocular myasthenia gravis (MG), according to an analysis of medical records from several hospitals in Japan. Although treatment was associated with favorable outcomes, some symptoms persisted in more than half the treated patients. Still, immunotherapy, including corticosteroids,…